ICS use may modify FEV1 decline in α1-antitrypsin deficiency patients with relatively high blood eosinophils
Respiration Jan 03, 2018
Low EV, et al. - This study was performed on patients with α1-antitrypsin deficiency (AATD), to assess their eosinophilia status against outcomes including mortality and FEV1 decline. In PiZZ AATD, inhaled corticosteroid (ICS) use to attenuate FEV1 decline was indicated by a persistent blood eosinophil levels >0.2 × 109/L.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
